Related Experiment Video

Updated: Aug 21, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Danielle Brazel1, Zhaohui Arter1, Misako Nagasaka1,2,3

  • 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.

Lung Cancer (Auckland, N.Z.)
|November 17, 2022
PubMed

Insights

KRAS G12C mutations are common in non-small cell lung cancer. Adagrasib (MRTX849) is a new KRAS G12C inhibitor showing promise in early studies for treating this difficult-to-target cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • KRAS G12C mutations are prevalent in non-small cell lung cancer (NSCLC), correlating with poor patient outcomes.
  • Targeting KRAS mutations has been challenging due to the protein's high affinity for GTP/GDP and lack of accessible binding sites.
  • Recent advancements have led to the development of selective KRAS G12C inhibitors.

Purpose of the Study:

  • To review the mechanism of action of adagrasib (MRTX849).
  • To discuss the pharmacokinetic and pharmacodynamic properties of adagrasib.
  • To summarize the efficacy and tolerability data for adagrasib in clinical studies.

Main Methods:

  • Review of preclinical and clinical data for adagrasib (MRTX849).
  • Analysis of published Phase I/II study results.
  • Evaluation of drug properties including mechanism, pharmacokinetics, pharmacodynamics, efficacy, and safety.

Main Results:

  • Adagrasib selectively inhibits the KRAS G12C oncoprotein.
  • Early clinical studies demonstrate promising efficacy and a manageable safety profile for adagrasib.
  • Pharmacokinetic and pharmacodynamic data support the potential for sustained target inhibition.

Conclusions:

  • Adagrasib represents a significant advancement in targeting KRAS G12C-mutated NSCLC.
  • The drug's properties suggest it could become a valuable therapeutic option for patients with this specific mutation.
  • Further clinical investigation is warranted to confirm its long-term benefit and optimal use.
Keywords:
KRASMRTX849non-small cell lung cancertargeted therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K